Skip to main content
logo
Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.470
-0.020 (-0.80%)
At close: Aug 27, 2026, 4:00 PM EDT
2.470
0.00 (0.00%)
After-hours: Aug 27, 2026, 4:10 PM EDT

Inhibikase Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.260.123.1
Revenue Growth
---111.03%-96.02%343.92%
Cost of Revenue
---13.6212.0311.36
Gross Profit
----13.36-11.91-8.26
Selling, General & Admin
27.4223.5611.386.736.226.51
Research & Development
38.822.3917.21---
Operating Expenses
66.2245.9528.596.736.226.51
Operating Income
-66.22-45.95-28.59-20.09-18.13-14.77
Interest Expense
------0.02
Interest & Investment Income
3.723.721.071.060.07-
EBT Excluding Unusual Items
-61.42-42.23-27.52-19.03-18.05-14.79
Asset Writedown
-7.4-7.4----
Other Unusual Items
0.221.37----
Pretax Income
-60.64-48.26-27.52-19.03-18.05-14.79
Net Income
-60.64-48.26-27.52-19.03-18.05-14.79
Net Income to Common
-60.64-48.26-27.52-19.03-18.05-14.79
Net Income Growth
------
Shares Outstanding (Basic)
1409824643
Shares Outstanding (Diluted)
1409824643
Shares Change
115.18%314.60%293.35%42.74%39.15%121.72%
EPS (Basic)
-0.43-0.49-1.16-3.16-4.28-4.87
EPS (Diluted)
-0.43-0.49-1.16-3.16-4.28-4.87
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-42.61-27.8-19.15-18.1-17.59-14.3
Free Cash Flow Per Share
-0.30-0.28-0.81-3.00-4.17-4.71
Gross Margin
------266.35%
Operating Margin
----7711.98%-14686.17%-476.23%
Profit Margin
----7304.73%-14625.86%-476.88%
Free Cash Flow Margin
----6947.87%-14253.37%-461.10%
EBITDA
-66.16-45.89-28.56-19.91-18.12-
D&A For EBITDA
0.050.060.030.180.01-
EBIT
-66.22-45.95-28.59-20.09-18.13-14.77
Revenue as Reported
---0.260.123.1
SEC Filings: 10-K · 10-Q